"Patient enrollment in our first Phase III study has continued to progress well and we have good visibility on the timeline with expected topline results in the fourth quarter of this year. The streng ...

London, 13 March, 2026, Claret Capital Partners (‘Claret’), Europe's largest independent growth debt fund manager has made an investment, through its Fund IV, of up to EUR 28 million in Cinclus Pharma ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Cinclus ...

"Cinclus Pharma has now entered late-stage clinical development following the initiation of its first Phase III study, and patient recruitment has so far progressed well. Topline results are expected ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

STOCKHOLM, March 4, 2020 /PRNewswire/ -- Cinclus Pharma Holding AB ("Cinclus Pharma") announced today that the company has successfully completed a financing round of SEK 250 million to fund the ...

STOCKHOLM, Aug. 18, 2021 /PRNewswire/ -- Cinclus Pharma Holding AB ("Cinclus Pharma"), a biopharmaceutical company focused on the development of a novel treatment for severe gastroesophageal reflux ...

Earnings call Cinclus Pharma delivered strong operational progress in Q1 2026, highlighted by near-complete enrollment in its pivotal HEEALING 1 phase III trial and robust financial flexibility with a ...

Also contributes to funding remaining development and pre-launch activities of Cinclus lead asset, linaprazan glurate, toward market approval and commercialisation London, 13 March, 2026, Claret ...

Cinclus Pharma is a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases Claret Capital Partners providing growth funding of up to €28M to ...

We believe Cinclus Pharma is uniquely positioned to deliver a best-in-class therapy, and we are proud to partner with the team at this pivotal moment.” This investment by Claret is one of a number of ...